These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

319 related items for PubMed ID: 29054682

  • 1. Liposomalization of oxaliplatin induces skin accumulation of it, but negligible skin toxicity.
    Nishida K, Kashiwagi M, Shiba S, Muroki K, Ohishi A, Doi Y, Ando H, Ishida T, Nagasawa K.
    Toxicol Appl Pharmacol; 2017 Dec 15; 337():76-84. PubMed ID: 29054682
    [Abstract] [Full Text] [Related]

  • 2. Multiple administration of PEG-coated liposomal oxaliplatin enhances its therapeutic efficacy: a possible mechanism and the potential for clinical application.
    Abu Lila AS, Eldin NE, Ichihara M, Ishida T, Kiwada H.
    Int J Pharm; 2012 Nov 15; 438(1-2):176-83. PubMed ID: 22944302
    [Abstract] [Full Text] [Related]

  • 3. Sequential treatment of oxaliplatin-containing PEGylated liposome together with S-1 improves intratumor distribution of subsequent doses of oxaliplatin-containing PEGylated liposome.
    Nakamura H, Doi Y, Abu Lila AS, Nagao A, Ishida T, Kiwada H.
    Eur J Pharm Biopharm; 2014 May 15; 87(1):142-51. PubMed ID: 24361534
    [Abstract] [Full Text] [Related]

  • 4. Intratumoral Visualization of Oxaliplatin within a Liposomal Formulation Using X-ray Fluorescence Spectrometry.
    Ando H, Abu Lila AS, Tanaka M, Doi Y, Terada Y, Yagi N, Shimizu T, Okuhira K, Ishima Y, Ishida T.
    Mol Pharm; 2018 Feb 05; 15(2):403-409. PubMed ID: 29287147
    [Abstract] [Full Text] [Related]

  • 5. Drug release rate influences the pharmacokinetics, biodistribution, therapeutic activity, and toxicity of pegylated liposomal doxorubicin formulations in murine breast cancer.
    Charrois GJ, Allen TM.
    Biochim Biophys Acta; 2004 May 27; 1663(1-2):167-77. PubMed ID: 15157619
    [Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9. Comparative plasma and tissue distribution of Sun Pharma's generic doxorubicin HCl liposome injection versus Caelyx® (doxorubicin HCl liposome injection) in syngeneic fibrosarcoma-bearing BALB/c mice and Sprague-Dawley rats.
    Burade V, Bhowmick S, Maiti K, Zalawadia R, Jain D, Rajamannar T.
    Cancer Chemother Pharmacol; 2017 May 27; 79(5):899-913. PubMed ID: 28349166
    [Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11. Oxaliplatin targeting to angiogenic vessels by PEGylated cationic liposomes suppresses the angiogenesis in a dorsal air sac mouse model.
    Abu-Lila A, Suzuki T, Doi Y, Ishida T, Kiwada H.
    J Control Release; 2009 Feb 20; 134(1):18-25. PubMed ID: 19010364
    [Abstract] [Full Text] [Related]

  • 12. Impact of formulation parameters and circulation time on PEGylated liposomal doxorubicin related hand-foot syndrome.
    Lian J, Tang X, Gui Y, Lu S, Song Y, Deng Y.
    Int J Pharm; 2024 Nov 15; 665():124659. PubMed ID: 39260752
    [Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15. Direct comparison of two pegylated liposomal doxorubicin formulations: is AUC predictive for toxicity and efficacy?
    Cui J, Li C, Guo W, Li Y, Wang C, Zhang L, Zhang L, Hao Y, Wang Y.
    J Control Release; 2007 Apr 02; 118(2):204-15. PubMed ID: 17239468
    [Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18. Pharmacokinetics of pegylated liposomal Doxorubicin: review of animal and human studies.
    Gabizon A, Shmeeda H, Barenholz Y.
    Clin Pharmacokinet; 2003 Apr 02; 42(5):419-36. PubMed ID: 12739982
    [Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20. Pharmacokinetics, efficacy and toxicity of different pegylated liposomal doxorubicin formulations in preclinical models: is a conventional bioequivalence approach sufficient to ensure therapeutic equivalence of pegylated liposomal doxorubicin products?
    Mamidi RN, Weng S, Stellar S, Wang C, Yu N, Huang T, Tonelli AP, Kelley MF, Angiuoli A, Fung MC.
    Cancer Chemother Pharmacol; 2010 Nov 02; 66(6):1173-84. PubMed ID: 20661737
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 16.